National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Talimogene laherparepvec (Imlygic®) is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.

 

Rapid Review

Commenced Completed Outcome
16/02/2016 14/03/2016 Full Pharmacoeconomic Evaluation Recommended.

Not considered cost-effective due to non-submission of full pharmacoeonomic evaluation